We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Top Analyst Reports for UnitedHealth, CVS Health & General Electric
Read MoreHide Full Article
Thursday, January 3, 2018
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH - Free Report) , CVS Health (CVS - Free Report) and General Electric (GE - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Buy-ranked UnitedHealth’s shares have outperformed the Zacks Medical Insurance industry's rally in the past year (up +8.5% vs. +7.8%). The Zacks analyst thinks the company's performance is being backed by higher revenues and strength in both segments — UnitedHealthcare and Optum — plus membership growth.
The company's robust Government business is also driving long-term growth. Its international business and strong capital position are the other positives. The company’s raised earnings guidance for 2018 and a strong initial 2019 guidance instills optimism among its investors. However, the company is experiencing membership decline in Commercial segment.
Shares of Buy-ranked CVS Health have underperformed the Zacks Retail Pharmacies and Drug Stores industry in the past six months, gaining +1.7% versus +4.5%. On November 29, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. The culmination of this huge deal marks the creation of a new healthcare powerhouse, which combines CVS Health’s broad pharmacy business with Aetna’s giant insurance base.
In this regard, the Zacks analyst thinks that over the past few quarters, the company has consistently demonstrated strong Pharmacy Services performance, benefiting from the upside in specialty services. Also, Retail/LTC comparisons are encouraging of late. Strong 2019 PBM selling season is another upside.
On the flip side, the company apprehends fewer RFP (Requests for Proposals) opportunities in the market than what it has seen over the past few years. Also, according to CVS Health, Omnicare business performance should continue to remain soft through the second-half of 2018.
General Electric’s shares have underperformed the S&P 500 index in the past three months (-36.4% vs. -13.3%). The Zacks analyst thinks the company is poised to become more competent on the back of its portfolio-restructuring program. In sync with this, it intends to focus on just three core businesses — Power, Aviation and Renewable Energy — and gradually exit all others.
Moreover, the company has slashed its dividend from 12 cents per share to a penny (for improving its cash position) and plans to reorganize the Power business into two separate units. However, weakening Power business remains a key cause of concern for the company. General Electric expects that internal and external challenges will continue to hurt this business arm.
Also, the company’s margins have been affected due to lower profits secured from its Renewable Energy business. Over the past seven days, the Zacks Consensus Estimate for the company’s earnings has remained unchanged for both 2018 and 2019.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Top Analyst Reports for UnitedHealth, CVS Health & General Electric
Thursday, January 3, 2018
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH - Free Report) , CVS Health (CVS - Free Report) and General Electric (GE - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Buy-ranked UnitedHealth’s shares have outperformed the Zacks Medical Insurance industry's rally in the past year (up +8.5% vs. +7.8%). The Zacks analyst thinks the company's performance is being backed by higher revenues and strength in both segments — UnitedHealthcare and Optum — plus membership growth.
The company's robust Government business is also driving long-term growth. Its international business and strong capital position are the other positives. The company’s raised earnings guidance for 2018 and a strong initial 2019 guidance instills optimism among its investors. However, the company is experiencing membership decline in Commercial segment.
(You can read the full research report on UnitedHealth here >>>).
Shares of Buy-ranked CVS Health have underperformed the Zacks Retail Pharmacies and Drug Stores industry in the past six months, gaining +1.7% versus +4.5%. On November 29, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. The culmination of this huge deal marks the creation of a new healthcare powerhouse, which combines CVS Health’s broad pharmacy business with Aetna’s giant insurance base.
In this regard, the Zacks analyst thinks that over the past few quarters, the company has consistently demonstrated strong Pharmacy Services performance, benefiting from the upside in specialty services. Also, Retail/LTC comparisons are encouraging of late. Strong 2019 PBM selling season is another upside.
On the flip side, the company apprehends fewer RFP (Requests for Proposals) opportunities in the market than what it has seen over the past few years. Also, according to CVS Health, Omnicare business performance should continue to remain soft through the second-half of 2018.
(You can read the full research report on CVS Health here >>>).
General Electric’s shares have underperformed the S&P 500 index in the past three months (-36.4% vs. -13.3%). The Zacks analyst thinks the company is poised to become more competent on the back of its portfolio-restructuring program. In sync with this, it intends to focus on just three core businesses — Power, Aviation and Renewable Energy — and gradually exit all others.
Moreover, the company has slashed its dividend from 12 cents per share to a penny (for improving its cash position) and plans to reorganize the Power business into two separate units. However, weakening Power business remains a key cause of concern for the company. General Electric expects that internal and external challenges will continue to hurt this business arm.
Also, the company’s margins have been affected due to lower profits secured from its Renewable Energy business. Over the past seven days, the Zacks Consensus Estimate for the company’s earnings has remained unchanged for both 2018 and 2019.
(You can read the full research report on General Electric here >>>).
Other noteworthy reports we are featuring today include ExxonMobil (XOM - Free Report) , Chevron (CVX - Free Report) and Stryker (SYK - Free Report) .
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>